However, it is important to note that plasma GLP-1 level is a predictor of poor CV outcomes in patients with acute MI [865], yet chronic pharmacological agonism of the GLP-1 receptor produces beneficial CV outcomes in patients with obesity and/or T2D. The gene discussed is GCG; the disease is obesity disorder.